News

January 6, 2017
Kala Pharmaceuticals to Present Update on Phase 3 Programs at the 35th Annual J.P. Morgan Healthcare Conference

April 13, 2016
Kala Pharmaceuticals Announces Closing of $68 Million Series C Financing

May 14, 2015
Kala Pharmaceuticals Appoints Mark Iwicki as Executive Chairman

May 1, 2015
Kala Pharmaceuticals to Present at the Association for Research in Vision and Ophthalmology 2015 Annual Meeting

April 16, 2015
Kala Pharmaceuticals Presents at the Ophthalmology Innovation Summit

April 1, 2015
Kala Pharmaceuticals Announces Positive Results from Phase 3 Trial of KPI-121 in Cataract Surgery

April 1, 2015
Kala Pharmaceuticals Announces Positive Results from Phase 2 Trial of KPI-121 in Dry Eye Disease

July 31, 2014
Kala Pharmaceuticals Initiates Phase 2 Clinical Trial to Evaluate LE-MPP (KPI-121) in Patients with Retinal Vein Occlusion and Diabetic Macular Edema

June 19, 2014
Kala Pharmaceuticals Initiates Phase 3 Clinical Trial for Treatment of Post-Surgical Ocular Inflammation and Phase 2 Clinical Trial in Dry Eye Disease

April 28, 2014
New Preclinical Data Demonstrate Kala Pharmaceuticals’ Topical LE-MPP Provides Equal or Better Drug Exposure Compared to Lotemax®

April 23, 2014
Kala Pharmaceuticals Announces $22.5 Million Series B Financing

January 6, 2014
Kala Pharmaceuticals Announces IND Submission of its MPP-Formulated Loteprednol Etonbonate (LE-MPP) for Post-Cataract Surgery

January 6, 2014
Kala Pharmaceuticals Appoints Howard B. Rosen as Chairman of the Board of Directors

November 13, 2013
Kala’s Ocular Disease Program Selected as a Top 10 Project to Watch

November 12, 2013
Kala Pharmaceuticals Presents Preclinical Data on Mucus Penetrating Particles at 2013 AAPS Annual Meeting and Exposition

November 5, 2013
Kala Pharmaceuticals to Present at 5th Annual Ophthalmology Innovation Summit @ AAO

October 4, 2013
Kala Pharmaceuticals to Present at Partnership Opportunities in Drug Delivery conference

October 2, 2013
Kala Pharmaceuticals to Present at BIO Investor Forum

September 24, 2013
pic-news-logo-fierce-15Kala Pharmaceuticals Named One of the “Fierce 15” Leading Biotech Companies of 2013

September 23, 2013
Kala Pharmaceuticals to Present at the Targeting Ocular Disorders Conference

August 8, 2013
Kala Pharmaceuticals to Present at the Canaccord Genuity Annual Growth Conference

July 22, 2013
Kala Presents Data Demonstrating Topical Delivery to Posterior Segment of the Eye

July 19, 2013
Kala Pharmaceuticals to Present Data at the Controlled Release Society 2013 Annual Meeting

May 28, 2013
Kala Pharmaceuticals Appoints Charles McDermott as Executive Vice President of Business Development

May 6, 2013
Kala Presents Data on Enhanced Topical Ocular Delivery of a Receptor Tyrosine Kinase Inhibitor

May 3, 2013
Kala Pharmaceuticals to Present Data at ARVO 2013 Annual Meeting

February 28, 2013
Kala Pharmaceuticals Secures $11.5 Million in Series A Financing

February 5, 2013
Kala Pharmaceuticals Appoints Kim Brazzell, PhD, as Chief Medical Officer

February 5, 2013
Kala Pharmaceuticals Receives Cystic Fibrosis Foundation Grant

November 27, 2012
Kala Pharmaceuticals Appoints Dr. Bernard Gilly to its Board of Directors

July 12, 2012
Kala Pharmaceuticals Appoints Guillaume Pfefer, PhD as President and CEO

July 12, 2012
Kala Pharmaceuticals Co-founder Publishes Data on Novel Therapeutic Approach to Overcome Mucosal Barrier for Prevention of Herpes Simplex Virus-2 Infection

March 14, 2012
Kala Pharmaceuticals Secures $6.2 Million in Additional Equity Financing